Key Points
- Insider purchase: Director Thomas Michael Tamberrino bought 13,908 shares on Dec. 23 at C$9.91 each (C$137,828 total), raising his stake to 39,241 shares — a 54.90% increase in ownership.
- Profound Medical trades around C$10.78 with a 52-week range of C$5.23–C$12.40 and a market cap of C$391.24M, but the company is unprofitable (negative P/E and margins); it reported C$0.26 EPS for the most recent quarter while analysts forecast about -1.90 EPS for the fiscal year.
- Business profile: Profound Medical is a commercial-stage medical device company whose lead product, the TULSA‑PRO, is an MRI‑guided, robotically driven system for incision‑free prostate tissue ablation.
-logo-1200x675.PNG?v=20210211152252)
Profound Medical Corp. (TSE:PRN - Get Free Report) insider Thomas Michael Tamberrino bought 13,908 shares of Profound Medical stock in a transaction dated Tuesday, December 23rd. The stock was purchased at an average price of C$9.91 per share, with a total value of C$137,828.28. Following the completion of the purchase, the insider owned 39,241 shares in the company, valued at C$388,878.31. This trade represents a 54.90% increase in their ownership of the stock.
Profound Medical Stock Up 0.7%
PRN stock opened at C$10.78 on Friday. The company has a debt-to-equity ratio of 20.05, a quick ratio of 14.98 and a current ratio of 6.12. Profound Medical Corp. has a fifty-two week low of C$5.23 and a fifty-two week high of C$12.40. The stock's 50 day simple moving average is C$10.11 and its 200 day simple moving average is C$8.34. The company has a market cap of C$391.24 million, a P/E ratio of -8.17 and a beta of 1.19.
Profound Medical (TSE:PRN - Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported C$0.26 earnings per share for the quarter. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%.The company had revenue of C$7.36 million for the quarter. On average, research analysts expect that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
